moxifloxacin has been researched along with clarithromycin in 125 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (clarithromycin) | Trials (clarithromycin) | Recent Studies (post-2010) (clarithromycin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 7,149 | 1,606 | 2,504 |
| Protein | Taxonomy | moxifloxacin (IC50) | clarithromycin (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 5.5 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3113 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.0903 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 57 (45.60) | 29.6817 |
| 2010's | 51 (40.80) | 24.3611 |
| 2020's | 17 (13.60) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J | 1 |
| Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Amaral, K; Dzink-Fox, J; Fischer, E; Goldovitz, J; Manni, K; Neckermann, G; Osborne, CS; Pecanka, R; Ryder, NS; Yu, D | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Appelbaum, PC; Beachel, L; Clark, C; Dewasse, B; Kosowska-Shick, KM; McGhee, P; Nagai, K | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Zhang, T | 1 |
| Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beyer, G; Edlund, C; Hiemer-Bau, M; Lode, H; Nord, CE; Ziege, S | 2 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Bottura, P; Capra, R; Maggiolo, F; Migliorino, M; Pravettoni, G; Suter, F | 1 |
| Esposito, S; Ianniello, F; Noviello, S | 1 |
| Amábile-Cuevas, CF; Hermida-Escobedo, C; Vivar, R | 1 |
| Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J | 1 |
| Bartolozzi, F; Cammarota, G; Candelli, M; Cremonini, F; Di Caro, S; Gasbarrini, A; Lupascu, A; Nista, EC; Ojetti, V; Zocco, MA | 1 |
| Bobbaers, H; Collins, O; Finch, R; Hoeffken, G; Izquierdo, JL; Kubin, R; McGivern, J; Nikolaides, P; Ogundare, F; Raz, R; Schürmann, D; Zuck, P | 1 |
| Binstock, P; Keating, M; Kontoyiannis, DP; Nannini, EC; Samonis, G | 1 |
| Duprat-Lomon, I; Lamping, DL; Marquis, P; Marrel, A; Sagnier, PP; Schroter, S | 1 |
| Corris, P; Duprat-Lomon, I; Höffken, G; Kubin, R; Muir, JF; Sagnier, PP; Torres, A | 1 |
| Allewelt, M; Beyer, G; Borner, K; Burkhardt, O; Lode, H; Nord, CE; Stass, H | 1 |
| Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS | 1 |
| Becker, DL; Chancellor, JV; Drummond, MF; Duprat-Lomon, I; Hux, M; Kubin, R; Sagnier, PP | 1 |
| Choudhri, S; Church, D; Grossman, C; Haverstock, D; Herman-Gnjidic, Z; Lode, H; McGivern, J | 1 |
| Allegra, L; Huchon, G; Izquierdo, JL; Jones, P; Sagnier, PP; Schaberg, T; Wilson, R | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L | 1 |
| Beecroft, MD; Herman-Gnjidic, Z; Marrie, TJ | 1 |
| Bermudez, LE; Carter, G; Young, LS | 1 |
| Cots, JM; Llor, C; Miravitlles, M; Molina, J; Naberan, K | 2 |
| Borrás, R; de Julián-Ortiz, JV; Domínguez, V; Gálvez, J; García-García, A; Guna, R; Muñoz, C | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Galley, HF; Watt, AM; Webster, NR; Williams, AC | 1 |
| Morovic, M | 1 |
| Lee, SB; Mohan, SK; Oliver, KM; Slomovic, AR; Strube, YN | 1 |
| Anzueto, A; Choudhri, S; Haverstock, D; Kureishi, A; Niederman, MS; Perroncel, R; Sethi, S | 1 |
| Käser, L; Naumann, UK; Steurer-Stey, C; Vetter, W | 1 |
| Espandar, L; Meyer, JJ; Moshirfar, M | 1 |
| Escribano, I; Flores, E; Garcia-Pachon, E; Rodriguez, JC; Royo, G; Ruiz, M | 1 |
| Bästlein, E; Haferland, C; Jebens, C; Kirsch, C; Knoth, H; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M; Zekorn, C | 1 |
| Decramer, M; Martin, M; Moore, L; Quilici, S; Simoens, S | 1 |
| Chauffour, A; Jarlier, V; Ji, B; Robert, J | 1 |
| Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
| Maley, M; Preda, VA; Sullivan, JR | 1 |
| Agnihotri, SP; Gupta, P; Gupta, S; Jain, NK; Sharma, KK | 1 |
| Bin, M; Donghai, W; Kehu, Y; Lijuan, Y; Quanlin, G; Wenzhen, Y; Yumin, L | 1 |
| Cremades, R; Garcia-Pachon, E; Rodríguez, JC; Royo, G; Ruiz, M; Santos, A | 1 |
| Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Bae, SM; Cheong, HJ; Choi, WS; Kim, MJ; Park, DW; Sohn, JW; Son, SW; Song, T; Yoon, YK | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Dan, M; Rosenberg, S; Samra, Z | 1 |
| Daza, RM; Lucena, JL; Ramos, A; Roustan, G | 1 |
| Girgis, DO; Karp, CL; Miller, D | 1 |
| Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F | 1 |
| Jeon, K; Koh, WJ; Shin, SJ | 1 |
| Andersen, AB; Iversen, M; Katzenstein, TL; Lillebaek, T; Mared, L; Qvist, T | 1 |
| Hong, G; Jeon, K; Jeong, BH; Kim, CK; Kim, SY; Koh, WJ; Kwon, OJ; Lee, SH; Park, HY; Shin, SJ | 1 |
| Alcántara, F; Atwood, SS; Becerra, MC; Bonilla, CA; Mitnick, CD; Seung, KJ | 1 |
| Herath, SC; Poole, P | 1 |
| Choi, YJ; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, JW; Nam, RH; Park, JH | 1 |
| Akdoğan, RA; Bedir, R; Copur, A; Rakici, H; Yilmaz, A | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Akdogan, RA; Ayaz, T; Bedir, R; Rakici, H | 1 |
| Hwang, JJ; Kim, N; Lee, AR; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Babrak, LM; Bermudez, LE; Rose, SJ | 1 |
| Ambati, BK; Archer, B; Cho, YK; Das, SK; Uehara, H | 1 |
| Bai, P; Ding, Y; Luo, Y; Xiao, XM; Zhou, LY | 1 |
| Brown-Elliott, BA; Chao, AS; Chiu, CH; Griffith, DE; Leu, HS; Lin, CS; Wu, TL; Wu, TS; Yang, CH | 1 |
| Cegiełkowska, M; Czopowicz, M; Dolka, B; Dolka, I; Ledwoń, A; Szeleszczuk, P | 1 |
| Hwang, JJ; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Cataldi, V; Cellini, L; Ciccaglione, AF; Di Bartolomeo, S; Di Campli, E; Di Giulio, M; Grossi, L; Marzio, L; Nostro, A | 1 |
| Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H | 1 |
| Aubry, A; Chauffour, A; Jarlier, V; Robert, J; Veziris, N | 1 |
| Olesen, JS; Wang, M; Wejse, C | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP | 1 |
| Chen, HC; Huang, CC; Huang, WC; Wu, MF | 1 |
| Jo, KW; Nam, GB; Shim, TS; Yoon, HY | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Fukao, A; Horikawa, S; Ikeue, T; Noguchi, S; Ohi, I; Sugita, T; Tanaka, E; Terashita, S; Yoshida, H | 1 |
| Hardin, JW; Hyche, S; Magagnoli, J; Sutton, SS | 1 |
| Chang, CH; Chang, YY; Lu, PH | 1 |
| Laidler, N | 1 |
| Kim, EK; Kim, SK; Kim, TI; Ko, J; Yong, DE | 1 |
| Chen, WL; Chu, HS; Hu, FR; Liu, HY; Wang, IJ | 1 |
| Astari, L; Cambau, E; do Nascimento, DC; Gillini, L; Grosset, J; Izumi, S; Kar, HK; Mieras, LF; Prakoeswa, CRS; Saunderson, PR; Scollard, DM; Smith, WCS; Sturkenboom, MGG; Taal, AT; van Brakel, WH; Virmond, MCL | 1 |
| Herath, SC; Maisey, S; Normansell, R; Poole, P | 1 |
| Andersen, ÅB; Gynthersen, R; Katzenstein, TL; Qvist, T | 1 |
| Fukui, M; Marumo, S; Shirata, M; Tamai, K; Yoshimoto, Y | 1 |
| Chang, CL; Chen, LC; Chien, JY; Hsueh, PR; Yu, CJ | 1 |
| Atsumi, T; Fujieda, Y; Iwasaki, N; Kamishima, T; Kono, M; Matsui, Y; Ninagawa, K | 1 |
| Adams, LB; Collins, JH; Hagge, DA; Lahiri, R; Lenz, SM; Ray, NA | 1 |
| Chonan, M; Fujimoto, Y; Ihara, H; Iwai, M; Kurokawa, K; Misawa, S; Nakamura, A; Ochi, Y; Ohsaka, A; Okabe, T; Shibayama, K; Sumiyoshi, I; Takahashi, K; Takei, S; Togo, S; Watanabe, J | 1 |
| Khandelwal, S; Malhotra, B; Sharma, M | 1 |
| Bader, JS; Danchik, C; Hoover, L; Karakousis, PC; Matern, WM; Parker, H | 1 |
| Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I | 1 |
| Akrami, S; Dokht Khosravi, A; Hashemzadeh, M | 1 |
| Abdrabou, AMM; Berger, FK; Bischoff, M; Gärtner, BC; Margardt, L; Mellmann, A; von Müller, L | 1 |
| Kato, M; Kobayashi, T; Suzuki, H | 1 |
| He, W; Li, Y; Liu, C; Ma, A; Qiu, Q; Zhao, Y | 1 |
| Daneshfar, S; Hashemzadeh, M; Khosravi, AD | 1 |
| Choi, SI; Jang, JY; Kim, N; Lee, DH; Lee, JW; Nam, RH; Song, CH | 1 |
| Arslan, N; Esen, N; Özkarataş, MH; Özkütük, AA | 1 |
| Giti, R; Mohammadi, F; Moradi, A; Rahmati, S; Ramezani, V; Tavakoli, F | 1 |
| Faksri, K; Hinwan, Y; Kaewprasert, O; Sirichoat, A | 1 |
9 review(s) available for moxifloxacin and clarithromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bronchitis, Chronic; Chronic Disease; Clarithromycin; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials.
Topics: Aza Compounds; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Moxifloxacin; Odds Ratio; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment | 2010 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Disease Progression; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic | 2013 |
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones | 2017 |
Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review.
Topics: Administration, Topical; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Follow-Up Studies; Humans; Keratitis; Keratomileusis, Laser In Situ; Male; Moxifloxacin; Mycobacterium avium Complex; Severity of Illness Index; Treatment Outcome | 2017 |
Bilateral Non-tuberculous Mycobacterial Keratitis After Small Incision Lenticule Extraction.
Topics: Administration, Ophthalmic; Administration, Oral; Amikacin; Anti-Bacterial Agents; Clarithromycin; Corneal Surgery, Laser; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Microsurgery; Moxifloxacin; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Myopia; Refraction, Ocular; Surgical Flaps; Tomography, Optical Coherence; Visual Acuity; Young Adult | 2018 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Disease Progression; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Roxithromycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
21 trial(s) available for moxifloxacin and clarithromycin
| Article | Year |
|---|---|
Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Candida; Clarithromycin; Double-Blind Method; Endospore-Forming Bacteria; Enterobacteriaceae; Enterococcus; Feces; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Gram-Positive Cocci; Humans; Intestines; Male; Moxifloxacin; Quinolines; Time Factors | 2000 |
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Community-Acquired Infections; Fluoroquinolones; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Moxifloxacin; Nasopharynx; Pneumonia, Bacterial; Quinolines | 2000 |
Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Candida; Clarithromycin; Cross-Over Studies; Double-Blind Method; Fluoroquinolones; Humans; Male; Moxifloxacin; Neisseria; Oropharynx; Prevotella; Quinolines; Streptococcus | 2000 |
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Confidence Intervals; Double-Blind Method; Female; Fluoroquinolones; Humans; Liver Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies; Quinolines; Recurrence; Treatment Outcome | 2001 |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Combinations; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Moxifloxacin; Omeprazole; Patient Compliance; Quinolines; Treatment Outcome | 2002 |
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2002 |
The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Psychometrics; Quality Assurance, Health Care; Quinolines; Surveys and Questionnaires | 2002 |
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Penicillins; Pneumonia; Quinolines | 2003 |
Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Clarithromycin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Feces; Fluoroquinolones; Half-Life; Humans; Intestines; Male; Metabolic Clearance Rate; Moxifloxacin; Oropharynx; Quinolines; Saliva | 2002 |
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Clarithromycin; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Naphthyridines; Pneumonia, Bacterial; Quinolines; Retrospective Studies; Treatment Outcome | 2003 |
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines | 2004 |
Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2004 |
Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Drug Therapy, Combination; Epidemiologic Methods; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Oxygen Inhalation Therapy; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2005 |
Q Fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Child; Clarithromycin; Coxiella burnetii; Doxycycline; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Q Fever; Quinolines; Treatment Outcome | 2005 |
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Mixed Function Oxygenases; Moxifloxacin; Polymorphism, Restriction Fragment Length; Prospective Studies; Quinolines; Rifabutin | 2008 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Multivariate Analysis; Odds Ratio; Pilot Projects; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Stomach Diseases; Time Factors; Treatment Outcome | 2015 |
Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Time Factors; Treatment Outcome | 2015 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Prevalence; Republic of Korea; Tertiary Care Centers | 2023 |
95 other study(ies) available for moxifloxacin and clarithromycin
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Clarithromycin; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Foot; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Quinolines; Rifampin; Streptomycin | 2007 |
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Topics: Animals; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Japan; Levofloxacin; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolines; Spleen | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
Topics: Acetamides; Amidohydrolases; Animals; Anti-Infective Agents; Female; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Peptides; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; Thigh | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
Topics: Anti-Bacterial Agents; Erythromycin; Luminescent Proteins; Microbial Sensitivity Tests; Models, Genetic; Mycobacterium ulcerans; Reserpine; Tetracycline | 2010 |
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
Topics: Anti-Bacterial Agents; Aza Compounds; Biofilms; Clarithromycin; Daptomycin; Fluoroquinolones; Microscopy, Electron, Scanning; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Vancomycin | 2010 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2000 |
Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Penicillin Resistance; Piperazines; Quinolines; Streptococcus pneumoniae; Streptococcus pyogenes; Time Factors | 2000 |
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Lactams; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Streptococcus pyogenes | 2001 |
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Ethambutol; Fatal Outcome; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linezolid; Male; Mefloquine; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Oxazolidinones; Quinolines | 2002 |
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Aza Compounds; Clarithromycin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mefloquine; Mice; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines | 2003 |
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluoroquinolones; France; Germany; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic | 2003 |
[Acute exacerbated chronic bronchitis. Antibiotics in comparison].
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Cefuroxime; Clarithromycin; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Smoking; Time Factors | 2003 |
Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Clarithromycin; Dose-Response Relationship, Drug; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2004 |
A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Biofilms; Clarithromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines | 2004 |
Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Clavulanic Acid; Cost of Illness; Cost-Benefit Analysis; Data Collection; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2004 |
In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium kansasii; Oxazolidinones; Quinolines | 2005 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
Differential effects of three antibiotics on T helper cell cytokine expression.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Clarithromycin; Cytokines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Interferon-gamma; Interleukin-4; Ionomycin; Lymphocyte Activation; Male; Middle Aged; Moxifloxacin; Quinolines; T-Lymphocytes, Helper-Inducer; Tetradecanoylphorbol Acetate; Th1 Cells; Th2 Cells | 2005 |
Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery.
Topics: Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Postoperative Complications; Quinolines; Surgical Flaps; Tobramycin | 2005 |
[Brochiectasis (in the adult)].
Topics: Adult; Aged; Aza Compounds; Bronchiectasis; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Immunization, Passive; Immunoglobulin M; Male; Moxifloxacin; Mycobacterium avium-intracellulare Infection; Paraproteinemias; Quinolines; Rifabutin; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia | 2007 |
Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Topics: Adult; Amikacin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines | 2007 |
Generation of resistant mutants of Mycobacterium chelonae and Mycobacterium fortuitum after exposure to subinhibitory concentrations of clarithromycin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium chelonae; Mycobacterium fortuitum; Quinolines | 2007 |
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; Cefuroxime; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2008 |
Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Clarithromycin; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Quinolines; Rifampin; Treatment Outcome | 2008 |
Mycobacterium chelonae infection in a tattoo site.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines; Tattooing | 2009 |
Extensively drug resistance (XDR) tb is not always fatal.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Aza Compounds; Capreomycin; Clarithromycin; Clofazimine; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; India; Injections; Male; Moxifloxacin; Quinolines; Sputum; Treatment Outcome | 2009 |
Activity of various drugs alone or in combination against Mycobacterium fortuitum.
Topics: Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Quinolines | 2010 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study.
Topics: Acupuncture Therapy; Amikacin; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Disease Outbreaks; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Korea; Male; Middle Aged; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Time Factors; Treatment Outcome | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum | 2011 |
[Development of subcutaneous nodules after mesotherapy].
Topics: Abscess; Adult; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Cutaneous Fistula; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mesotherapy; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines; Skin Diseases, Bacterial; Staining and Labeling; Subcutaneous Tissue | 2011 |
Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Aza Compounds; Child; Child, Preschool; Clarithromycin; Combined Modality Therapy; Corneal Ulcer; Eye Infections, Bacterial; Female; Florida; Fluoroquinolones; Humans; Incidence; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ophthalmologic Surgical Procedures; Quinolines; Retrospective Studies; Risk Factors; Surgical Wound Infection; Young Adult | 2012 |
Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; beta-Lactams; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Vaccination; Young Adult | 2012 |
Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Aza Compounds; Bronchiectasis; Clarithromycin; Female; Fluoroquinolones; Humans; Lung Diseases; Moxifloxacin; Mycobacterium; Quinolines | 2013 |
First report of lung transplantation in a patient with active pulmonary Mycobacterium simiae infection.
Topics: Anti-Bacterial Agents; Aza Compounds; Bronchiectasis; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung Transplantation; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Quinolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2013 |
Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Humans; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Rifampin; Sputum | 2013 |
Salvage therapy for multidrug-resistant tuberculosis.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Capreomycin; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Male; Moxifloxacin; Mycobacterium tuberculosis; Retrospective Studies; Rifampin; Salvage Therapy; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; DNA Gyrase; DNA Mutational Analysis; Drug Combinations; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genotyping Techniques; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Point Mutation; Republic of Korea; RNA, Ribosomal, 23S; Sensitivity and Specificity | 2014 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics.
Topics: Anti-Bacterial Agents; Biofilms; Cell Line; Clarithromycin; Deoxyribonuclease I; DNA, Bacterial; Drug Resistance, Bacterial; Epithelial Cells; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium avium | 2015 |
Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Cornea; Corneal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Immunohistochemistry; Keratitis; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Moxifloxacin | 2016 |
Susceptibility of Helicobacter pylori to antibiotics in Chinese patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Minocycline; Moxifloxacin; Peptic Ulcer; Risk Factors; Young Adult | 2015 |
Postcesarean section wound infection caused by Mycobacterium massiliense.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Cesarean Section; Chaperonin 60; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Humans; Imipenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Mycobacterium Infections; Nontuberculous Mycobacteria; Pregnancy; Surgical Wound Infection; Teicoplanin | 2016 |
Multidrug therapy of Mycobacterium avium subsp. avium infection in experimentally inoculated budgerigars (Melopsittacus undulatus).
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Galliformes; Male; Melopsittacus; Moxifloxacin; Mycobacterium avium; Tuberculosis, Avian | 2015 |
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Dyspepsia; Female; Fluoroquinolones; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pyloric Antrum; Rifabutin; Tetracycline; Young Adult | 2016 |
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2016 |
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Diarylquinolines; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium ulcerans; Rifampin | 2016 |
Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy.
Topics: Adrenal Cortex Hormones; Aged; Amputation, Surgical; Anti-Bacterial Agents; Arthritis, Rheumatoid; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Hand; Humans; Injections; Injections, Intra-Articular; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Tenosynovitis | 2017 |
In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Cycloserine; Drug Synergism; Fluoroquinolones; Gentamicins; Humans; Linezolid; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Sputum; Streptomycin | 2018 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Failure; Treatment Outcome | 2017 |
Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement.
Topics: Clarithromycin; Cough; Dyspnea; Exudates and Transudates; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections; Pleurisy; Tomography, X-Ray Computed | 2017 |
Appraisal of the cardiovascular risks of azithromycin: an observational analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Clarithromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face.
Topics: Adipose Tissue; Adult; Anti-Bacterial Agents; Clarithromycin; Cosmetic Techniques; Diagnosis, Differential; Face; Female; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Postoperative Complications; Tissue and Organ Harvesting; Transplantation, Autologous | 2017 |
Cutaneous infection with paucibacillary
Topics: Anti-Bacterial Agents; Antitubercular Agents; C-Reactive Protein; Clarithromycin; Diagnosis, Differential; Female; Fingers; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis, Cutaneous | 2017 |
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.
Topics: Anti-Bacterial Agents; Clarithromycin; Fluoroquinolones; Humans; Leprosy; Moxifloxacin; Netherlands; Post-Exposure Prophylaxis; Rifampin | 2018 |
Mycobacterium brisbanense lung infection facilitated by steroid induced adrenal insufficiency.
Topics: Adrenal Insufficiency; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Humans; Male; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Respiratory Tract Infections; Sputum | 2019 |
In vitro efficacy of combinations of eight antimicrobial agents against Mycobacteroides abscessus complex.
Topics: Actinomycetales Infections; Amikacin; Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacteriaceae; Sequence Analysis, DNA | 2020 |
Different clinical features of patients with pulmonary disease caused by various Mycobacterium avium-intracellulare complex subspecies and antimicrobial susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium avium; Mycobacterium avium-intracellulare Infection; Taiwan; Young Adult | 2020 |
Non-tuberculosis Mycobacterium Tenosynovitis with Rice Bodies in a Patient with Systemic Lupus Erythematosus.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Female; Fingers; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium Infections; Symptom Flare Up; Tenosynovitis | 2020 |
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
Topics: Animals; Asymptomatic Infections; Bacterial Load; Clarithromycin; Drug Combinations; Leprostatic Agents; Leprosy; Mice; Mice, Nude; Minocycline; Moxifloxacin; Mycobacterium leprae; Post-Exposure Prophylaxis; Rifampin | 2020 |
The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Combinations; Drug Synergism; Female; Humans; Imipenem; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2020 |
Drug susceptibiity testing of nontuberculous mycobacteria by broth microdilution method.
Topics: Amikacin; Anti-Bacterial Agents; Clarithromycin; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin | 2021 |
Genetic Determinants of Intrinsic Antibiotic Tolerance in Mycobacterium avium.
Topics: Anti-Bacterial Agents; Clarithromycin; DNA Transposable Elements; Drug Therapy, Combination; Drug Tolerance; Ethambutol; Humans; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifabutin | 2021 |
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline | 2022 |
Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study.
Topics: Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Humans; Iran; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin; Tuberculosis | 2023 |
Implementation of a Clostridioides difficile sentinel surveillance system in Germany: First insights for 2019-2021.
Topics: Anti-Bacterial Agents; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cross Infection; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Moxifloxacin; Multilocus Sequence Typing; Ribotyping; Rifampin; Sentinel Surveillance | 2022 |
Case of Moxifloxacin-Induced Black Hairy Tongue.
Topics: Aged; Clarithromycin; Female; Humans; Moxifloxacin; Tongue; Tongue, Hairy | 2022 |
Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China.
Topics: Amikacin; Clarithromycin; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis; Rifabutin | 2022 |
Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran.
Topics: Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Humans; Iran; Laboratories; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Tuberculosis | 2022 |
[Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
Topics: Amikacin; Anti-Bacterial Agents; Cefoxitin; Ciprofloxacin; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Tobramycin | 2023 |
Development and characterization of a copolymeric micelle containing soluble and insoluble model drugs.
Topics: Clarithromycin; Drug Carriers; Micelles; Moxifloxacin; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Spectroscopy, Fourier Transform Infrared | 2023 |
Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand.
Topics: Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Phylogeny; Thailand | 2023 |